NCT02184338View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

November 30, 2004

Conditions
Healthy
Interventions
DRUG

BIBR 1017 BS powder

DRUG

Placebo

PEG 400

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02184338 - Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects | Biotech Hunter | Biotech Hunter